Professor Mary Glenn Fowler is a paediatrician and clinical researcher who has focused her research career on HIV prevention and treatment in the U.S. and internationally. She received her BA from the U. of Washington, her Medical degree from U. of Oregon Health Sciences, completed her pediatric residency at Wake Forest Medical Center, Bowman Gray School of Medicine and did a fellowship in Developmental Pediatrics at U of North Carolina-Chapel Hill., NC. She then stayed on as faculty in Department of Pediatrics UNC-Chapel, until she moved to the DC area, and did an MPH at Johns Hopkins U. School of Public Health, after which she worked on prevention of mother to child transmission of HIV and pediatric HIV treatment at the Division of AIDS, NIAID from 1991-1999; then for six years at CDC before moving to The Johns Hopkins U. School of Medicine, where she worked onsite at the Makerere U. Johns Hopkins U. (MU-JHU) Research Collaboration in Kampala Uganda from 2005 through 2014. Dr. Fowler then moved back to Johns Hopkins U. School of Medicine, Baltimore MD.
For the past three decades Dr. Fowler has devoted her research career to the prevention of mother to child transmission (PMTCT); along with treatment and care for HIV infected mothers, children; and more recently to HIV prevention among high-risk women and adolescents. During her research career, Dr. Fowler has helped support a number of cutting-edge HIV prevention and treatment clinical trials in both Africa and the Far East (Thailand and India). These trials have contributed to our knowledge of PMTCT and treatment interventions which are safe, efficacious and deliverable in resource-limited settings among breastfeeding HIV Infected women; to optimizing antiretroviral treatment regimens that optimize overall maternal and child survival; and to highly efficacious and safe PrEP among high-risk women and adolescents.
Her international research has included the landmark HIVNET 12 trial, as well as multiple other PMTCT trials addressing ways to reduce the risk of transmission from mothers to infants during both pregnancy and breastfeeding. These trials including the CDC funded Kisumu Breast milk open-label trial conducted in 2003-2005, which assess the safety and efficacy of maternal ART for PMTCT, as well as two large trials assessing the safety and efficacy of infant NVP to prevent transmission during breastfeeding, the PEPI trial conducted in Malawi and the multisite HPTN 046. Most recently Dr. Fowler chaired the IMPAACT PROMISE 1077BF and 1077FF trials which were conducted at 15 African and 1 Indian site that compared the efficacy/safety of maternal ART to other effective regimens.
The IND PROMISE trial has provided clinical trial data to support WHO’s recommendations for use of maternal ART both for PMTCT and maternal treatment.
Prof. Fowlers also served as Co-Chair of the Perinatal Working Group for HIVNET and HPTN and as DAIDS Medical Officer for multiple PMTCT trials and was a member of the USPHS Guidelines group for many years that developed guidelines for US perinatal HIV treatment recommendations. Dr. Fowler currently serves as JHU Kampala CTU PI for the DAIDS/NIAID Network trials; and also have been funded for two related R01 trials focused on longer-term outcomes of ART for both mothers and their HIV ART exposed infants; and served as a PD/PI o an adherence intervention study among HIV infected mothers, working with Dr. Philippa Musoke. Dr. Fowler looks forward to serving on the Advisory Board for the MU-JHU Research Collaboration.